Life Sciences and Material Sciences Stephan B. Tanda Member Managing Board Royal DSM Volkert Claassen VP White Biotechnolgy Royal DSM Carnegie Bank, Denmark, 1 May 2009 0
Safe Harbor Statement This presentation may contain forward-looking statements with respect to DSM s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this presentation, unless required by law. The English language version of this document is leading. A more comprehensive discussion of the risk factors affecting DSM s business can be found in the company s latest Annual Report, which can be found on the company's corporate website, www.dsm.com 1
DSM is everywhere 2
Agenda Operational performance Q1 2009 Vision 2010 update Biobased businesses 3
Highlights Q1 2009 DSM reports profitable Q1 despite difficult economic conditions Q1 operating profit down to EUR 57 million Continuing strong performance from Life Sciences businesses Most Materials Sciences businesses severely impacted by downturn Continued strong cash performance, EUR 166 million cash from operating activities No quantitative outlook provided for 2009 in view of uncertain economic conditions 4
Q1 Results 2009 - Key figures ( million) Q1-09 Q1-08 % before exceptional: Net Sales 1,837 2,358-22% EBITDA 167 338-51% EBIT 57 237-76% Net Profit 25 162-85% EPS 0.13 0.95-84% including exceptional items: Net Profit 13 162-92% EPS 0.06 0.95-94% 5
Agenda Operational performance Q1 2009 Vision 2010 update Biobased businesses 6
Focus on Life Sciences and Material Sciences Climate and Energy Health and Wellness Functionality and Performance Emerging Economies Life Sciences Materials Sciences Nutrition Pharma EBAs Performance Materials Polymer Intermediates Exploiting strong market positions and technology platforms 7
Balanced portfolio in economic downturn 2008 Sales per Cluster 2008 Sales per end-market Nutrition Pharma 10% Performance Materials Other 19% 14% Food 31% 26% Fibers/ Textiles 8% 15% Feed 20% Base Chemicals and Materials 13% Polymer Intermediates Electrical & Electronics Transportation/ Automotive 4% 8% Building & Construction 9% Pharma 4% 10% 9% Agriculture Packaging Nutrition, Pharma and DSM Dyneema relatively unaffected 8
Actions addressing the economic downturn Good progress with implementation of saving actions All projects identified Savings expected to clearly exceed 100m Workforce reduction of more than 1000 positions Full savings will be achieved in 2010 Capex expected to be lower than 2008, focused on future growth (e.g. DSM Dyneema) Contingency plans prepared in case conditions do not improve DSM remains committed to customers, innovation and sustainability Total savings expected to exceed 100m by approx. 25% 9
Commitment to innovation Core Businesses Life Sciences Materials Sciences Additional innovation expenditure Managing the pipeline Intrinsically Innovative Company Accelerated Growth Areas Emerging Business Areas NBD Acquisitions > 75m p/a Venturing 60m 200m Top 50 projects Best practices Business opportunities Investments Management To ~ 1bn by 2010 from 600m in 2008 Intrinsically innovative company 10
Innovation sales growth towards 1bn in 2010 million 1000 800 800m 1.0bn 600 600m 400 350m 200 0 170m 2006 2007 2008 2009 2010 Nutrition Performance Materials Pharma/Others All clusters Sales 2008 600m, 1bn target in 2010 11
Summary Q1 2009 profitable despite difficult economic conditions Half of the portfolio relatively unaffected Total savings expected to exceed 100m by approx 25%, Contingency plans in preparation in case conditions do not improve Successful cash generation due to focus Strong balance sheet and financial flexibility DSM remains committed to sustainability DSM is Staying the course 12
Agenda Operational performance Q1 2009 Vision 2010 update Biobased businesses 13
Unique position in bio-based businesses Life Sciences Material Sciences New platforms Food, Feed + additives Biofuels Bio Food, Feed + additives New cases ~ 1.5 billion Biomedical Thermoplastics Dyneema Pharma Bio Pharma Biochemicals Active packaging Thermosets/ Resins BioPerformance Materials Approx. 1.5 billion sales and ample innovation opportunities 14
Understanding the emerging new value chain Feedstock Provision Feedstock Processing Primary Conversion Secondary Conversion Bio Compounds & formulation Converters Farming Storage Distribution Grain seed milling Biomass pretreatment - enzymatic conversion Fermentation Chemical conversion Enzymatic conversion Polymerization Chemical Synthesis Compounding Formulation Reactive Extrusion Moulding Film extrusion Food & Feed Bio Medical Coatings Automotive Life Sciences Material Sciences Pharma Personal Care Electrical Know how on end-markets needs and capabilities to make it happen 15
Four multi-billion US$ market opportunities Biofuels Bio Chemical/ Materials Biomedical Materials Biopharma Ingredients US$ 50bn (> 15%) Estimated market size 2010 and growth US$ 20bn (> 15%) US$ 2bn (10-15%) US$ 14bn (> 15%) Portfolio enables crossover innovation in high potential markets 16
Exciting developments in biomedical materials BIOSTABILITY BIOCOMPATIBILITY BIO-INTERACTIVE US$ 1.2bn market 10-15% growth High margins US$ 0.9bn market 15-20% growth Very high margins US$ 30-60m market 40-60% growth High margins Coatings and Implants Coatings Polymer enabled anddrug Implants delivery Coatings Polymer Regenerative enabled anddrug Medicine Implants delivery DSM: Leadership position in biomedical materials 17
Replicating the natural function of the human disc Axiomed lumbar disc with DSM PTG polymer for replacement of body parts Treating degenerative disc disease Aims to restore natural function of the spine In clinical trial phase Market growth (US): US$ 55m ( 07) to US$ 440m (2013) Nutrition Pharma Performance Chemical Biotech Material Materials Synthesis Sciences 18
Novel polymer drug delivery platform Trancerta Treatment of vascular and ophthalmic diseases For customized drug delivery systems Contract manufacturing services through DPP In pre-clinical development phase Accelerating time to market through an exclusive world-wide license from Medivas Nutrition Pharma Performance Chemical Biotech Material Materials Synthesis Sciences 19
DSM s current biotechnology markets Biospecialties Food ingredients Pharmaceuticals Fine chemicals Biomaterials Agricultural (by)products Chemo-physical treatment and/or enzymes Sugars Biochemicals : Cell factory: Biocatalysis - or Micro-organisms Biofuels Ethanol Hydrogen 20
DSM s future in white biotechnology Biospecialties Food ingredients Pharmaceuticals Fine chemicals Biomaterials Agricultural (by)products Chemo-physical treatment and/or enzymes Sugars Biochemicals : Cell factory: Biocatalysis - or Micro-organisms Biofuels Ethanol Hydrogen Expansion in biobased endmarkets 21
DSM track record in modern biotechnology Maxiren for cheese industry Arachidonic acid for infant nutrition Cephalosporin Vitamin B2 Aldolases for cholesterol lowering drug 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 Strong innovation record as a basis for further growth 22
Food/feed/pharma products via biotechnology Carbo hydrates Fermentation organism Enzymes Food / Feed Pharma Cargill ADM Abengoa Roquette Novozymes Danisco BASF LeSaffre Lallemand DSM DSM frontrunner in chemical sector in implementing biotechnology 23
Biofuels builds on existing knowledge Carbo hydrates Enzymes Yeast Biofuels Cargill ADM Abengoa Roquette Novozymes Danisco Verenium DSM LeSaffre Lallemand DSM Yeasts are crucial for the conversion of sugars into biofuels 24
Biofuels from 1 st to 2 nd generation First generation Second generation Need for new and sustainable energy resources 25
Innovation challenges 2 nd generation biofuels Pre-treatment Enzymatic Hydrolysis Yeast Fermentation C6/C5 Yeast Cellulosic material Pulp Sugars Biofuels New enzymes and yeasts will be necessary to convert plant residuals 26
Replacing chemistry by biotech an example Old Route New Route Penicillium Sugar Sugar chrysogenum Traditional Fermentation Metabolic Engineering 13 chemical steps 2 enzymatic steps 27
Replacing chemistry by biotech an example Old Route New Route Penicillium Sugar Sugar chrysogenum Traditional Fermentation 13 chemical steps Metabolic replaced Engineering by: 1 fermentation + 2 enzymatic steps 65% less energy and materials 50% lower cost 13 chemical steps 2 enzymatic steps 28
Replacing chemistry by biotechnology Carbo hydrates Enzymes Yeast Bio-fuels Oil Chemistry Polymerization Materials 29
New opportunities from the combination Carbo hydrates Enzymes Fermentation organism Bio-fuels Bio-fuels BioChemicals BioPolymers Chemistry/ Enzymology Chemistry Polymerization Polymerization BioMaterials Materials Resulting in a broad range of innovative bio-based businesses 30
Succinic acid production at DSM DSM produces succinic acid chemically in Linz Austria Global production succinic acid (derivatives): ~ 25.000 T/Y Succinic acid used in: Food (acidulant, flavor) Coatings (car finish) Coolant (engines) Pharmaceuticals (building block) 31
Why bio succinic acid? Producing succinic acid via biological routes has several advantages: 1. Lower environmental impact 1. No use of fossil fuels (crude oil), bio-renewable feedstocks 2. Absorbs instead of emits CO 2 3. Cost proposition allows for high volume green chemicals and materials 2. New biobased & biodegradable applications feasible 1. Production of green plastics like PBS (for a.o. agricultural films) 2. Biobased fibers for clothing 3. Biobased resins (e.g. polymer of bio-succinic acid and isosorbide]) Nutrition Pharma Performance Chemical Biotech Material Materials Synthesis Sciences 32
A new era for the chemical industry Stanyl Pipeline PHA PLA PBS(X) NOP PA APC UPR PTT Epoxy Propanediol Succinic Acid Lactic Acid Vegetable oils Hydroxy Alkanoates Isosorbide other Biobased will take a significant part of oil based chemistry 33
Example: biodegradable plastics No need to remove from land Fishes injured by old non-degradable nets Waste in seas is risk for shipping (e.g. nets in screw propellers) Biomaterials as accelerator for sustainable solutions 34
Succinic acid demonstration plant Operational end of 2009 35
Contact: DSM P.O. Box 6500, 6401 JH Heerlen, The Netherlands ' (+31) 45 578 2864 7 (+31) 45 578 2595 e-mail: investor.relations@dsm.com internet: www.dsm.com visiting address: Het Overloon 1, Heerlen, The Netherlands 36